Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Pharmaceutical
The Bill & Melinda Gates Medical Research Institute (Gates MRI) has appointed Patrice Matchaba, as chief executive (CEO), starting June 10, 2024. 29 May 2024
Biotechnology
Shares of Swedish biotech Calliditas Therapeutics shot up more than 78% to 202.60 kronor by late afternoon, on news of a takeover bid from Asahi Kasei. 28 May 2024
Biotechnology
Australia’s Neuren Pharmaceuticals has announced top-line results from its Phase II trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). 28 May 2024
Pharmaceutical
USA-based Nippon Shinyaku subsidiary NS Pharma has published a disappointing initial analysis from an important trial of Viltepso (viltolarsen). 28 May 2024
Pharmaceutical
Australia’s Dimerix saw its shares leap 25% to A$0.42 on Monday, as it announced a licensing agreement with Taiba Middle East FZ. 28 May 2024
Biotechnology
Privately-held US Biotech Human Immunology Biosciences (HI-Bio) has announced positive interim results from the randomized, placebo-controlled Phase II IGNAZ study of the investigational CD38 antibody felzartamab in the treatment of IgA nephropathy (IgAN). 27 May 2024
Biotechnology
UK pharma major AstraZeneca’s chief executive Sir Pascal Soriot outlined ambitious plans to increase revenue by nearly 75% to $80 billion by 2030. On the research front, US healthcare giant Johnson & Johnson released positive new data on its Tremfya in the treatment of ulcerative colitis (UC), and US biotech Tango Therapeutics announced that it is discontinuing development of its investigational cancer drug TNG348 due to toxicity. Also of note, the US Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation for Cartesian Therapeutics’ myasthenia gravis candidate Descartes-8. 26 May 2024
Pharmaceutical
Already a blockbuster diabetes and weight loss drug sold by Novo Nordisk under the brand names Ozempic, Rybelsus and Wegovy, semaglutide’s standing has been further enhanced by new findings. 24 May 2024
Biotechnology
Californian company Cytokinetics closed Thursday’s trading down 17% after announcing a couple of updates that will add $1 billion to its cash pile. 24 May 2024
Pharmaceutical
The European Commission (EC) has approved the label update of both Nilemdo (bempedoic acid) and Nustendi (bempedoic acid / ezetimibe fixed-dose combination (FDC)), as treatments for hypercholesterolaemia (high levels of cholesterol) and to reduce the risk of adverse cardiovascular events. 24 May 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze